« Previous
Next »
Titles
- S. 1730: in the House of Representatives : June 10, 1886 : read twice and referred to the Committee on Commerce : June 22, 1886 : reported with amendments, committed to the Committee of the whole House on the state of the Union, and ordered to be printed : omit the parts struck through and insert the parts printed in italics : An act providing for the appointment of a commission to investigate the truth of alleged discoveries of the specific cause of yellow fever, and of a method of preventing that disease by inoculation, and to obtain all information possible as to the cause and prevention of that disease1
- S. 1730: in the Senate of the United States : March 3, 1886 : Mr. Eustis, from the Committee on Epidemic Diseases, submitted a report (no. 185) accompanied by the following bill, which was read the first and second times by unanimous consent : A bill providing for the appointment of a commission to investigate the truth of alleged discoveries of the specific cause of yellow fever, and of a method of preventing that disease by inoculation, and to obtain all information possible as to the cause and prevention of that disease1
- S. 2518: in the Senate of the United States : January 9, 1885 : Mr. Palmer introduced the following bill : which was read twice and reffered to the Select Committee to Invesitage and Report the Best Means of Preventing the Introduction and Spread of Epidemic Diseases : A bill to prevent the introduction and diffusion of contagious and infectious diseases in the United States, and to promote the general sanitary welfare of the people1
- S. 780: in the Senate of the United States : December 21, 1885 : Mr. Logan introduced the following bill, which was read twice and referred to the Committee on Commerce : April 22, 1886 : Reported by Mr. McMillan with amendments, viz: omit the part struck through and insert the parts printed in italics : a bill to regulate appointments in the Marine Hospital Service of the United States1
- S11 nonclinical safety testing in support of development of pediatric pharmaceuticals1
- S12 nonclinical biodistribution considerations for gene therapy products: guidance for industry1
- S1B(R1) addendum to S1B testing for carcinogenicity of pharmaceuticals: guidance for industry1
- S3A guidance: note for guidance on toxicokinetics : the assessment of systemic exposure in toxicity studies : focus on microsampling : questions and answers1
- S5(R3) detection of reproductive and developmental toxicity for human pharmaceuticals1
- S9 nonclinical evaluation for anticancer pharmaceuticals: questions and answers1
- SAMHSA is missing opportunities to better monitor access to medication-assisted treatment through the buprenorphine waiver program1
- SCHIP at the crossroads: California's options in responding to new federal funding conditions1
- SHAP enrollment and eligibility activities: implications for process and system modernization under national health reform1
- SIM "stack" in Minnesota: a case study of Otter Tail County Public Health1
- SSA disability programs: better metrics and evaluation needed to inform decision-making : testimony before the Subcommittee on Social Security, Committee on Ways and Means, House of Representatives1
- SSA's Compassionate Allowance Initiative: improvements needed to make expedited processing of disability claims more consistent and accurate : report to the Chairman, Subcommittee on Social Security, Committee on Ways and Means, House of Representatives1
- SSA's Compassionate Allowance initiative: actions needed to improve the accuracy and consistency of expedited processing of disability claims : testimony before the Subcommittee on Social Security, Committee on Ways and Means, House of Representatives1
- SSI for disabled immigrants: why do ethnic networks matter?1
- Sacramento area: large health systems grow in a pricey and tumultuous market1
- Sacramento: health providers collaborate and weather economic downturn1